此次暂停的临床试验是 2seventy 首次在人体上测试其药物调控的CAR-T细胞平台,其希望通过这项研究为未来CD33靶点和实体瘤靶点的CAR-T研究奠定基础。 参考资料: https://ir.2seventybio.com/news-releases/news-release-details/2seventy-bio-announces-...
此次暂停的临床试验是2seventy首次在人体上测试其药物调控的CAR-T细胞平台,其希望通过这项研究为未来CD33靶点和实体瘤靶点的CAR-T研究奠定基础。 参考资料 : https://ir.2seventybio.com/news-releases/news-release-details/2seventy-bio-announces-clinical-study-pause-plat-08-trial-sc...
Background: The myeloid associated antigen CD33 is overexpressed in over 88% of Acute myeloid leukemia (AML) patients, making it a suitable target antigen for CAR T cell therapy across different genetic subtypes. Despite the development of clinical trial data, there remains a concern about on-tar...
Here, we present early safety and efficacy of functionally enhanced CD33 CAR T cells in AML.Methods:We improved the performance of CD33 CAR T cells by adding a potentiating molecule linked to human CD33 scFv by P2A. The study was registered with ClinicalTrials.gov (NCT04835519). The trial ...
(eHSCs) for the treatment of cancer, today announced an exclusive licensing agreement with the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), for intellectual property related to a clinical-stage anti-CD33 chimeric antig...
We initiated a single-center, single-arm, Phase I clinical trial (NCT03126864) to investigate the feasibility and safety of autologous T cells, modified to express a CD33-targeted CAR with 4-1BB and CD3ζ endo-domains and co-expressed with truncated human epidermal growth factor receptor (HER...
2 项与CD33 Targeted CAR-NK(Goethe University) 相关的文献(医药) 2018-01-01·American journal of cancer research3区 · 医学 Erratum: First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia. Article ...
Moreover, as sorting of T cells is not feasible for clinical application, we also implemented a third dual-targeting strategy, called Triple-T, which mimics the natural product of co-transduction, encompassing CAR-T, TCR-T, and CAR’TCR-T in equal proportions. No significant difference was ...
Preclinical studies demonstrated that AMG330 (in the presence of activated human T-cells) could improve the survival of mice by suppressing the growth of a subcutaneous AML cell line xenograft [25]. AMG330 is currently being studied in a phase I clinical trial (NCT02520427) with various ...
In an animal model, CD33 CAR-NK cells demonstrated increased antileukemia efficacy, comparable to that of CD33 CAR-T-cell therapy. We designed a phase I clinical trial to evaluate the safety and preliminary efficacy of CD33 CAR-NK cells in AML....